Of the 49 cases, many did not seek medical attention due to the mild sensory symptoms. Symptom duration most commonly lasted for 2–4 days, and in all cases, symptoms resolved within 2 weeks. The onset of focal neurological symptoms was within 24 h of vaccination in a majority of patients and within 7 days in all. Headaches were sometimes, but not always, part of the clinical picture as well. Among these 49 patients, unilateral sensory disturbance was the most frequent focal symptom hemiparesis occurred less often but was more disabling. According to our post-vaccination surveillance record, 49 of the total 15.747 patients (0.31%) were reported to have focal neurological symptoms. None received a second dose of the ChAdOx1 vaccine. There were 2553 individuals to whom first doses of the ChAdOx1 vaccine were administered. Īs of May 9, 2021, at King Chulalongkorn Memorial Hospital, 13,194 individuals had been administered first doses of the CoronaVac vaccine, and among them, 4064 s doses were administered. This work was presented as an abstract at the World Congress of Neurology (WCN 2021) in Rome, Italy (3–7 October 2021). Here we present eight cases of this immunization-related focal neurological syndrome that underwent extensive investigation in our hospital. Interestingly, these unusual presentations and findings were consistent among the patients. After thousands of injections in our hospital, several more cases have been consulted by the neurology team for further evaluation as acute stroke was suspected. The very first case report regarding this phenomenon was published in this journal. However, after mass vaccination, cases with a distinctive, novel focal neurological syndrome have begun to emerge nationwide among those receiving CoronaVac. Both were approved by the Thai Food and Drug Administration. The COVID-19 vaccination program in Thailand started in February 2021, with the two available vaccines at that time being CoronaVac (Sinovac Biotech, China) and ChAdOx1 (AstraZeneca/Oxford, UK). Neurologic complications of COVID-19 vaccination are rare, but reported definite and possible nervous system adverse events have included cerebral venous thrombosis, Guillain-Barre syndrome, postural orthostatic tachycardia, and immunization stress-related response. The Creative Commons Public Domain Dedication waiver ( ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |